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The functional maturation of dendritic cells (DC) 
and other antigen-presenting cells is believed to re-
flect the upregulation of cell surface major histocom-
patibility complex (MHC) class II and other T cell co-
stimulatory molecules, especially the CD28 ligands 
B7-1 (CD80) and B7-2 (CD86). In this study, we prop-
agated cells exhibiting characteristics of DC precur-
sors from the bone marrow (BM) of BIO mice (H_2b ; 
I-A +) in response to granulocyte-macrophage colony 
stimulating factor (GM-CSF). The methods used were 
similar to those employed previously to propagate DC 
progenitors from normal mouse liver. Cells expressing 
DC lineage markers (NLDC 145+, 33Dl +, N418+) har-
vested from 8-tO-day GM-CSF stimulated BM cell cul-
tures were CD45+, heat-stable antigen+, CD54+, 
CD44+, MHC class 11+, B7_1dbn but B7-2- (costimula-
tory molecule-deficient). Supplementation of cultures 
with interleukin-4 (IL-4) in addition to GM-CSF how-
ever, resulted in marked upregulation of MHC class II 
and B7-2 expression. These latter cells exhibited po-
tent allostimulatory activity in primary mixed leuko-
cyte cultures. In contrast, the cells stimulated with 
GM-CSF alone were relatively weak stimulators and 
induced alloantigen-specific hyporesponsiveness in 
allogeneic T cells (C3H; H_2k; I-E+) detected upon re-
stimulation in secondary MLR. This was associated 
with blockade of IL-2 production. Reactivity to third-
party stimulators was intact. The hyporesponsiveness 
induced by the GM-CSF stimulated, costimulatory 
molecule-deficient cells was prevented by incorpora-
tion of anti-CD28 monoclonal antibody in the primary 
MLR and was reversed by addition of IL-2 to restimu-
lated T cells. The findings show that MHC class 11+ 
B7-2- cells with a DC precursor phenotype can induce 
alloantigen-specific hyporesponsiveness in vitro. Un-
der the appropriate conditions, such costimulatory 
molecule-deficient cells could contribute to the induc-
tion of donor-specific unresponsiveness in vivo. 
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The functional maturation of dendritic cells (DC)* and 
other antigen-presenting cells is now thought to reflect the 
upregulated expression of cell surface major histocompatibil-
ity complex (MHC) class II and T cell costimulatory mole-
cules, especially the CD28 ligands B7-1 (CD80) and B7-2 
(CD86) (I, 2). "Mature" DC are powerful inducers of naive T 
cell activation (3, 4). It has been suggested, however, that 
their functionally "immature" precursors, that are deficient 
as inducers of allogeneic T cell responses, may have the 
capacity to function as tolerogenic cells (5-7). 
The liver is comparatively rich in DC (8, 9) and other 
leukocyte lineages compared with the heart or kidney. It is 
thought, however, to be the least immunogenic of whole 
organ allografts (10-12). In mice, it can be transplanted 
successfully between many strains despite MHC disparities 
and without immunosuppression. Moreover, it induces per-
manent, donor-specific unresponsiveness (12). This has led to 
the hypothesis that the liver possesses tolerogenic (as well as 
immunogenic) properties. Previously, we have reported that 
DC progenitors cultured from normal liver are capable of 
extensive proliferation in vitro in response to granulocyte-
macrophage colony-stimulating factor (GM-CSF) (7). These 
cells fail to stimulate allogeneic T cells in vitro, but migrate 
in vivo to T-dependent areas of allogeneic secondary lym-
phoid tissue (13). Therein at least some of the liver-derived 
cells strongly express donor MHC class II and persist for 
months, recapitulating the fate of donor-derived leukocytes 
up to 1 year after transplantation in non-immunosuppressed 
liver allograft recipients (12, 14). 
Recently, we have shown that small numbers of DC pro-
genitors expressing donor (male) phenotype (MHC class I, II 
and Y-chromosome) can be propagated from the BM of un-
modified (female) murine liver allograft recipients in re-
sponse to GM-CSF (15). These findings have provoked ques-
tions about the function of donor-derived, DC lineage cells in 
relation to tolerance induction. Using techniques developed 
by Inaba et al. (16) and modified in this laboratory, we have 
propagated cells with characteristics of DC progenitors from 
mouse BM in response to GM-CSF. We report here on the 
function of these cells. They were found to be immunologi-
cally "immature" compared with BM-derived DC propagated 
in GM-CSF + IL-4. Whereas the GM-CSF + IL-4 induced DC 
were MHC class II+ B7-1 + B7-2+ and potent allostimula-
tors, the cells stimulated with GM-CSF alone were MHC 
* Abbreviations: APC, antigen-presenting cell; BM, bone marrow; 
DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimu-
lating factor; IL, interleukin; mAb, monoclonal antibody; MHC, ma-
jor histocompatibility complex; MLR, mixed leukocyte reaction. 
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class II+ B7_1dim B7-2-. Moreover, they induced alloanti-
gen-specific hyporesponsiveness of purified T cells in primary 
mixed lEiukocyte reactions (MLR). These findings may be of 
importance in furthering our understanding of the mecha-
nisms of tolerance induction following organ transplantation 
and in the development of new therapeutic strategies aimed 
at the prevention of their rejection. 
MATERIALS AND METHODS 
Animals. C57BUIOJ (BI0; H_2b, I_Ab, I-E-), C3H1HeJ (C3H; 
H_2k, I_Ak, I_Ek) and BALB/c (H-2d, I_Ad, I-E+) mice 10-12 weeks old 
were obtained from The Jackson Laboratory, Bar Harbor, ME. They 
were maintained in a specific pathogen-free animal facility of the 
University of Pittsburgh Medical Center. 
Propagation of bone marrow (BM)-derived cells. Bone marrow 
(BM) cell suspensions were prepared in RPMI-I640 (Gibco, Grand 
Island, NY) using conventional procedures. Cells (2X 106 ) were cul-
tured iii 24-well plates in RPMI-1640 supplemented with 10% v/v 
fetal bovine serum (Gibco) and 500U (2 ng)/ml recombinant(r) mouse 
GM-CSF (Schering-Plough, Kenilworth, NJ). In some experiments, 
culture medium was supplemented with r mouse IL-4 (Schering-
Plough; 1000 U/ml) in addition to GM-CSF. The procedure used was 
modified (71 after that described by Inaba et a1. (16) for the propa-
gation of large numbers of DC progenitors from normal mouse BM. 
The medium containing GM-CSF was refreshed every two days; after 
gentle swirling of the plates, half the "old" medium was aspirated 
and an equivalent volume of RPMI-1640 with GM-CSF ± IL-4 was 
added. An objective of this manipulation was to deplete nonadherent 
granulocytes without dislodging clusters of developing DC that at-
tached loosely to a monolayer of firmly plastic-adherent macro-
phages. Morphologic and phenotypic analyses of typical single, non-
adherent mononuclear cells released spontaneously from the 
clusters were performed between 6 and 10 days. These cells were 
tested for their capacity to stimulate allogeneic T cells. 
Staining of cell surface and intracellular antigens. Cell surface 
staining was analyzed by cytofluorography using a FACScan flow 
cytometer <Becton Dickinson, Mountain View, CAl. Staining with 
primary hamster or rat monoclonal antibodies (mAbs), including rat 
anti-B7-1 and B7-2 (PharMingen, San Diego, CAl was followed by 
FITC-conjugated goat anti-hamster or mouse anti-rat Igs, as de-
scribed (7. Ill. MHC class 1 and class II-positive cells were identified 
using biotin-conjugated mouse anti-mouse mAbs (PharMingen, San 
Diego, CAl with FITC streptavidin (Jackson Immunoresearch, West 
Grove. PA) as the secondary reagent. After staining, the cells were 
fixed in 1% paraformaldehyde in saline before analysis. MAbs to 
MHC class II antigens and to the 2Al murine DC-restricted granule 
antigen were tested on cytospin preparations as described elsewhere 
(]6. 17). The specimens were fixed in acetone and stained with 
biotinylated mouse anti-MHC class II or rat anti-2A1 mAbs. fol-
lowed by streptavidin biotin peroxidase complex (ABC-P; Boehringer 
Mannheim. Indianapolis. IN) or peroxidase-conjugated anti-rat Ig, 
respectively. The nuclei were counterstained with hematoxylin. 
Mixed leukocyte reactions (MLR). Splenocytes for use as responder 
cells were depleted of red blood cells by lysis in Tris-buffered NH.Cl 
then T-cell enriched l >95%) by sequential removal of plastic-adher-
ent cells (1 hr at 37°C) and high-affinity negative selection by pas-
sage (10 min at room temperature I through a mouse T cell enrich-
ment column (R & D Systems. Minneapolis. MN). For MLR. 2x 105 T 
cells were cultured with graded concentrations of 'Y-irradiated (20 
Gyl allogeneIc stimulator cells in 0.2 ml of medium for 3 days in 
96-well. round-bottomed tissue culture plates in 5% Cl~ in air. 
Testing lor T cell hyporesponsiveness. For primary MLR. 2x lOti T 
cells were Incubated with 1 x 10° stimulators in 24-well plates in 2 ml 
of medium. In some experiments. hamster anti-CD28 mAb (Phar-
Mingen; 25 ~g/mlF or control hamster IgG was added to the primary 
MLR. After 2 days, the cells were harvested. washed in medium. and 
depleted of Ia - cells with anti-I-A" mAb tPharmingenl plus low-
toxicity rabbit complement (Accurate Chemical & Scientific, West-
bury, NY) (7). Viable cells were isolated by centrifugation over Ficoll-
Isopaque for 15 min at 350 xg.and rested in medium for 2 days in the 
absence of stimulators. The pretreated T cells were then restimu-
lated with freshly isolated 'Y-irradiated spleen cells in the absence or 
presence ofr hQIllan IL-2 (Gibco; 50U/ml) in a secondary, 3-day MLR 
in 96-well round-bottomed plates. For the final 18 hr, 10 iJl [3H]TdR 
(1 ",Ci) was added to each well. Cultures were harvested onto glass 
fiber disks using a multiple cell harvester and the degree of thymi-
dine incorporation was determined in a liquid scintillation counter. 
Results were expressed as mean cpm ± 1 SD. 
IL-2 assay. IL-2 levels in MLR culture supernatants were deter-
mined by the CTLL assay. CTLL cells (ATCC, Rockville, MD; 5 x 1031 
well) in exponential growth phase were suspended in RPMI-1640 
containing 10% FCS and incubated in flat-bottomed microtiter wells 
for 48 hr with dilutions of these supernatants or various concentra-
tions of standard rIL-2 (Gibco). [3H]TdR incorporation was assessed 
as described above. IL-2 production was determined by comparing 
the CTLL [3H]TdR incorporation supported by supernatants with 
that supported by known concentrations of rIL-2. Results were ex-
pressed as mean U IL-21ml ± 1 SD. 
RESULTS 
Propagation of cells from bone marrow. In previous stud-
ies, aggregates of growing DC progenitors have been de-
scribed in GM-CSF-stimulated cultures established from 
mouse BM (16), blood (18), spleen (17), or liver (7). Similar 
techniques were used to propagate DC progenitors from the 
BM of BI0 mice. In view of reports that GM-CSF + IL-4 is 
much more effective than GM-CSF alone in inducing DC 
maturation (19), this cytokine combination was also tested. 
Whether GM-CSF was used alone or in combination with 
IL-4, the floating cells released from the clusters and har-
vested at 6-10 days exhibited morphological characteristics 
of DC; dendritic morphology was especially prevalent in cells 
stimulated with both cytokines. 
Immunophenotypic analysis of GM-CSF stimulated cells. 
Cytospins were used to further characterize the released 
cells. By day 10, the majority expressed moderate levels of 
MHC class II. Granulocytes were rare. Most cells also 
strongly expressed the DC-restricted cytoplasmic granule an-
tigen 2Al (16, 17). To further characterize the surface immu-
nophenotype of the cells released from proliferating aggre-
gates, flow cytometric analysis was performed after 8-10 
days of culture in GM-CSF. Staining for cells of lymphoid 
lineage, including NK cells was absent. As shown in Figure 1. 
however, the floating cells in 8-l0-day BM-derived cultures 
expressed surface antigens that are known to be associated 
with mouse DC. These included CD45 <leukocyte-common 
antigen), MHC class I, heat stable antigen (JllDl, CD54 
(intercellular adhesion molecule-I; ICAM-l.l, CDllb (MAC-
ll. and CD44 (nonpolymeric determinant of Pgp.l glycopro-
tein). In addition. staining of moderate intensity was ob-
served for the mouse DC-restricted cell surface markers 
NLDC-145 (interdigitating cells). 33Dl and CDllc (N418; 
{:l2-integrin!, for the macrophage antigen F4/80. and fur 
FcyRII (CD32), as described previously (]6) for BM-derived 
DC. Expression of the low-affinity IL-2 receptor (CD25l could 
not be demonstrated. In agreement with the cytospin results, 
the GM-CSF-stimulated BM-derived cells expressed moder-
ate levels of cell surface MHC class II (l_Ah). 
Enhanced expression of MHC class II and of B7-1 and 
B7-2 by GM-CSF + IL-4-stimulated BM-derived cells. Cells 
stimulated with GM-CSF either alone or in combination with 
December 27. 1995 LV ET AL. 1541 
a: 
UJ 
0:1 
:E 
~ 
Z 
..J 
..J 
UJ 
U 
i'j A 1 C045 !1 H-2K' ~~ 8220 ~l~ C03 'I CD4 1i1lKi~1iK 
'1 C08 ~j NK1.l!· MAC·l !1 F4I8O I] Ai Fc-tR1l 
.. 1 LLLL 
!' N418!', NLDC145 ~l 3301 '1 ~ Jll 0 ~l A. 1 CD44 llg~KgtlIK~~ 
'1' IL·2R -i ICAM-l - 87·' - 87·2 -, loA' 
· "1: "L" 
.L1QL ... "",.",L 
LOG FLUORESCENCE INTENSITY 
FIGURE 1. FACScan immunophenotypic profiles of GM-CSF-stimu-
lated BID (H_2b ) mouse BM-derived cells released from cell aggre-
gates in liquid culture (day 10) and examined using rat, hamster, or 
mouse mAbs, Further details are provided in Materials and Methods 
or have been described elsewhere (7). Vnshaded profiles denote 
appropriate Ig isotype subclass controls. Note the absence of expres-
sion of lymphoid cell markers and the staining for three murine 
DC-restricted antigens NLDC 145, N41B (CDllc) and 33D!. The 
result is representative of 4 separate experiments, 
IL-4 were harvested after 8-10 days and compared for the 
expression of surface markers linked with allostimulatory 
activity. A marked difference was consistently observed be-
tween the two cell populations with respect to the intensity of 
expression of MHC class II and the CD28 ligands, B7-I 
(CD80) and B7-2 (CD86). As shown in Figure 2, MHC class 
II was positive and B7-1 expression was low, whereas B7-2 
was negligible/dim on cells stimulated with GM-CSF (500V/ 
m}) alone. An increase in GM-CSF concentration from 500-
1000 V/ml augmented the intensity of staining for each of 
these molecules (data not shown). However, expression of 
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FIGURE 2. Expression of MHC class II (l_Ab ), B7-l and B7-2 on 
(above) 8-day GM·CSF and (below) 8-day GM·CSF + IL-4-stimu-
lated BID BM-derived bone marrow cells. The result is representa-
tive of 3 separate experiments. 
MHC class II, and especially B7-2, was markedly and con· 
sistently upregulated on cells treated with both cytokines 
(Fig. 2). Similar results were obtained with GM·CSF + IL-
4-stimulated BM·derived cells from BlOBR and C3H mice. 
The GM·CSF·stimulated MHC class II+ B7_1dim B7-2- and 
the GM·CSF + IL-4-induced MHC class II+ B7-1 + B7-2+ 
populations are subsequently referred to herein as B7-2-
and B7-2+, respectively. 
MLR stimulatory activity of B7-2- and B7-2+ cells. As 
shown in Figure 3, the GM·CSF + IL-4-stimulated BIO 
BM-derived cells that were MHC class II+, B7-I + and B7-2+ 
were highly potent inducers of primary allogeneic (C3R) T 
cell responses in 3-day primary mixed leukocyte cultures. 
The possibility that this high MLR stimulatory activity was 
due to "carry· over" of IL·4 was excluded as GM·CSF + IL-
4-stimulated syngeneic B7-2+ cells did not induce T cell 
proliferation. On the basis both of immunophenotype and T 
cell stimulatory activity, the B7-2+ cells were considered to 
be predominantly "mature" DC. In contrast, GM-CSF stim-
ulated MHC class II+ B7-2- BM-derived cells were much 
poorer inducers of allogeneic T cell activation and exhibited a 
comparatively low level of MLR·stimulatory activity. This 
was consistent with their low level of cell surface B7-2 and 
similar to that of freshly isolated bulk BIO spleen cells. The 
B7-2- cells were therefore considered to be functionally "im· 
mature," DC progenitors. 
100 
..-
M 
Q 
... 
>< 
E 
Co 
~ 
c: 
o 
:;:: 
~ 10 
o 
Co 
.. 
o 
(J 
c: 
10 100 1000 
Stimulator Cell Number (X103) 
FIGURE 3. The MLR stimulatory capacity of BID (H-2b ) mouse BM-
derived cells (day 8) propagated in response to (0) GM·CSF (B7-2-) 
or (e) GM-CSF + IL-4 (B7-2+). Graded concentrations of washed, 
y-irradiated stimulator cells were cultured with 2x 105 purified al-
logeneic (C3H; H-2k) T cells. The stimulatory activity of freshly· 
isolated ("') BlO and (.) C3H (syngeneic) spleen cells and of (D) 
GM·CSF + IL-4 stimulated (C3Rl syngeneic cells is also shown. 
Cells were pulsed with [3H1TdR for the final 18 hr of 3-day cultures. 
The results are expressed as mean counts per minute (cpm):tl SD 
and are representative of three separate experiments. 
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Induction of alloantigen-specific hyporesponsiveness by 
B7-2- BM-derived cells. We considered that deficiency in 
cell surface expression of the B7-2 molecule might be asso-
ciated with the induction of hyporesponsivenessianergy by 
these cells. We therefore tested the capacity of the B7-2-
cells to induce alloantigen-specific anergy during a primary 
MLR. Purified C3H splenic T cells were stimulated initially 
with either freshly isolated BIO bulk spleen cells or GM-CSF 
stimulated (B7-2-) or GM-CSF + IL-4-stimulated (B7-2+) 
BIO BM cells; after resting for 2 days, the primed C3H T cells 
were restimulated in a secondary MLR with fresh BlO, C3H 
(syngeneic) or BALB/c (third-party) splenocytes. AB shown in 
Figure 4, the T lymphocytes stimulated with B7-2+ BIO cells 
in a primary MLR displayed strong proliferative responses 
when restimulated with BIO spleen cells. In contrast, T cells 
exposed initially to B7-2- BIO BM cells responded only 
weakly upon restimulation with BIO splenocytes and at a 
lower level than C3H T cells primed with fresh BIO spleno-
cytes. The same T cells however, displayed proliferative re-
sponses to third-party (BALB/c) spleen cells (Fig. 5), indicat-
ing that the hyporesponsiveness was donor-specific. 
Anti-CD28 mAb prevents hyporesponsiveness induced by 
B7-2- BM-derived cells. It is recognized that blockade of the 
CD28 costimulatory pathway can induce alloantigen-specific 
hyporesponsiveness (20) or tolerance (21). We therefore de-
termined whether the addition of anti-CD28 mAb to primary 
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FIGURE 4, Stimulation with B7-2 - BM-derived cells during a pri-
mary MLR induces hyporesponsiveness upon restimulation in sec-
ondary MLR. C3H splenic T cells (2x 10"/ml at 1:2 [S:Rll ratio were 
stimulated during a 2-day primary MLR with y-irradiated (0) GM-
CSF-stimulated BlO BM-denved cells (B7-2-). (el GM-CSF + IL-
4-stimulated BlO BM-derived cells (B7-2 '). or ('" ) fresh B10 spleen 
cells. The T cells were repurified and rested for 2 days, then restim-
ulated for 3 days with graded concentrations of freshly isolated B 10 
spleen cells. The results are expressed as mean cpm :!: 1 SO and are 
representative of four separate experiments, 
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FIGURE 5. T cells primed by B7-2- BM-derived cells are specifically 
hyporesponsive to donor alloantigens. C3R splenic T cells were stim-
ulated during a 2-day primary MLR with either ( "') freshly-isolated 
B10 bulk spleen cells or (0) B7-2- B10 cells. They were repurified, 
rested for 2 days, and restimulated for 3 days with C3H, BlO or 
BALB/c (third party) spleen cells. Results are expressed as mean 
counts per minute (cpm) :!: 1 SO and are representative of 3 separate 
experiments. 
MLR cultures could reverse the capacity of B7-2- cells to 
induce T cell hyporesponsiveness. The presence of anti-CD28 
mAb significantly increased the allostimulatory function of 
the costimulatory molecule-deficient cells. Furthermore, as 
shown in Figure 6, priming of allogeneic T cells with B7-2-
cells in the presence of anti-CD28 prevented hyporesponsive-
ness in secondary MLR. 
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FIGURE 6. Addition of anti-C028 mAb (25 p.g/mj) to primary MLR 
can prevent T cell hyporesponsiveness induced by B7-2- BM-derived 
cells. C3H splenic T cells were stimulated during a 2-day primarv 
:\1LR with (OJ. fresh BlO spleen cells; (.), B7-2- BlO cells; (u) 
B7-2- B10 cells + hamster IgG or (f]), or B7-2-- B10 cells + anti-
C028. The T cells were repurified. rested for 2 days, and restimu-
lated in 3-day secondary MLR with freshly isolated B10 spleen cells. 
The results are expressed as mean counts per minute lepml :!: 1 SO 
and are representative of three separate experiments, 
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Hyporesponsiveness induced by B7-2- cells is associated 
with impaired IL-2 production. To determine whether the 
induction of hypo responsiveness in C3R T cells was linked to 
blockade ofIL-2 production, levels ofIL-2 were determined in 
supernatants harvested from BIO restimulated T cells 
primed initially with BIO splenocytes, B7-2- BI0 cells, or 
B7-2- BI0 cells in the presence of anti-CD28. As shown in 
Table 1, C3R T cells primed with B7-2- cells failed to pro-
duce IL-2 in 2° MLR. The presence of anti-CD28 in the 1° 
MLR however, prevented subsequent unresponsiveness. 
T cells primed by B7-2- cells respond normally to alloan-
tigen + IL-2 in 2° MLR. There is evidence that IL-2 can 
prevent or reverse hyporesponsiveness in T cells anergized 
by antigen stimulation in the absence of costimulatory sig-
nals (20). Table 2 demonstrates that the hyporesponsive T 
cells primed by B7-2- BM-derived cells responded normally 
to alloantigen + exogenous IL-2 (50 U/ml) added at the outset 
of secondary stimulation. Indeed, T cell proliferation was 
enhanced. Collectively, these data strongly suggest the im-
portance of an IL-2 production defect in the induction of the 
hyporesponsive state. They also indicate that IL-2R expres-
sion was not affected, as the T cells responded vigorously to 
IL-2 in secondary MLR. 
DISCUSSION 
In contrast to classic mature DC (3), NLDC 145+, MRC 
class II+, B7-1 dim, B7-2- mouse BM-derived cells propa-
gated in GM-CSF induced alloantigen-specific hyporespon-
siveness in T cells upon rechallenge in vitro. This hypore-
sponsive state was inhibited by stimulation via the CD28 
pathway and reversed by exogenous IL-2. It was also found in 
this study that BM cells stimulated with GM-CSF + IL-4 
exhibited an overall similar phenotype to those propagated in 
GM-CSF alone. but stained intensely for B7-2 in addition to 
enhanced B7-1 and high MRC class II expression. In con-
trast to the B7-2- population, these cells were very potent 
allostimulators. The findings are consistent with those of 
Hathcock et al. (22), who showed that quantitative differ-
ences in B7-1 and B7-2 expression on murine APC (B cellsl 
could profoundly affect their contribution to costimulatory 
function (22), 
The influence of cytokines and cytokine combinations on 
B7-2 expression and DC maturation has been reported. Thus 
Larsen et al. (1) found that GM-CSF or IFN-y induced increased 
expression of B7-2 on cultured murine spleen DC and that 
GM-CSF also increased the expression of ICAM-1 and HSA. 
Only partial reduction of B7-2 expression was achieved, how-
ever, by the addition of anti-GM-CSF to skin cultures (2). Re-
cently, Sallusto and Lanzavecchia (19) have shown that cul-
tured human blood DC expanded in GM-CSF + IL-4 are highly 
stimulatory in MLR and considerably more potent than those 
induced with GM-CSF alone. The present finding, that GM-
CSF plus IL-4 markedly upregulated cell surface B7-2 expres-
sion and allostimulatory activity suggests that IL-4 may also be 
an important costimulatory cytokine for the functional matura-
tion of BM DC. Interestingly, although mouse small resting B 
cells induce anergy following exposure to IL-4, they express 
B7-1 and B7-2 molecules and stimulate lymphokine produc-
tion and proliferation in Thl clones (23). Blocking of B7-1, 
however, does not affect the ability of IL-4-treated B cells to 
stimulate Thl cell activation (22). 
MHC class II+ APC that are costimulatory molecule defi-
cient may (as is the case with inhibition of B7-2 [22]) allow 
TCR-mediated signaling events to occur but inhibit the dis-
tinct costimulatory signal(s) necessary for optimal cytokine 
production and cytokine-dependent T cell proliferation. 
Thus, antigen presentation by APC that are unable to deliver 
adequate costimulatory signals induces neither of the tran-
scription factors NF-AT or NF-kB (24). Absence of IL-2 ex-
pression during the induction of T cell anergy may be attrib-
uted to the normal induction (during the stimulation 
response) of a repressor factor(s) and the establishment of a 
stable, nontranscriptionally active IL-2 gene complex. As 
shown by others (25) and in the present study, the induction 
of hyporesponsiveness or anergy in murine T cells can be 
prevented by CD28 stimulation using mAb. Several adhesion 
receptor-ligand pairs however, such as ICAM-1-LFA-l can 
costimulate T cell proliferation. Nevertheless, B7 but not 
ICAM-! induces detectable IL-2 secretion and prevents the 
induction of alloantigen-specific anergy (26). Expression of 
both ICAM-! and RSA on the B7-2- cells in our system may 
account for T cell hyporesponsiveness as opposed to the in-
duction of anergy. 
The induction of irreversible T cell anergy to donor-specific 
alloantigens in vivo (tolerance) would, in theory, eliminate 
the need for potentially toxic, nonspecific immunosuppres-
sive agents that currently constitute first choice antirejection 
therapy. There has thus been considerable interest in evi-
dence that blockade of the B7-CD28 T cell costimulatory 
pathway is both necessary and sufficient to induce antigen-
specific T cell anergy (27). Although the costimulatory sig-
nals delivered to T cells by APCs are neither antigen-specific 
nor MHC-restricted, they determine the outcome of TCR 
signaling as they mediate cytokine secretion. Co-ligation of 
the T cell CD28/CTLA-4 receptors (an essential stimulus ofT 
cell activation) (28) by the APC counter-receptors B7IBBI 
(CD80l or the recently identified B701B7-2 (CD86) (29-,11) 
results in IL-2 production and T cell proliferation (28, 29, 3]), 
TABLE 1. HyporesponslVeness induced by 87-2 . B10 BM cells in primary MLR is associated with impaired IL-2 production a and is 
prevented by anti-CD28 
1 MLR:stlmulalOrs 
C3H spleen cells (syngeneic) 
B10 spleen cells 
87-2- BI0 8M cells 
B7-2 - BI0 BM cells + hamster IgG 
87-2 - B 108M cells.,. anti-CD28 
a CTLL cell proliferation I U IL-21mll. 
h ND = not done. 
25 
O.67:!:O.17a 
1.38:!:O.17 
O.84:!:O.13 
NDh 
2.1S:!:O.11 
2" MLRBIO stImulators \ x 10.1 ) 
50 
1.22:!:O.26 
4.68:!:O.S3 
1.30:!:O.10 
1.75:!:O.14 
7.S5:!:l.lO 
100 
2.49:!:O.18 
5.72:!:O.1l 
1.99:!:O.20 
1.82:!:O.14 
7.76:!:1.-l4 
! I 
I 
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TABLE 2. C3H T cells primed by B7-2- B10 BM cells respond normally to alloantigen + IL-2 in 2° MLR: [3H] TdR uptake 
(cpmX 103:t1 sm 
1° MLR:stimulators 11.-2 (50U/mll Ob 
B10 spleen cells 7.86:!:0.68 
+ ND" 
B7-2- B10 BM cells 10.79:!:0.28 
+ ND 
" Fresh spleen cells. 
b 105 C3H (syngeneic) spleen cell stimulators used as control. 
eND = not done. 
It is thought that this is achieved by increased IL-2 mRNA 
transcription (32, 33) or by increased mRNA stability (34). 
Elicitation of strong IL-2 production by T cells has long been 
recognized as a characteristic of antigen-presenting DC (35, 
36). 
While functional "immaturity" is evident in freshly isolated 
DC from mouse BM, spleen (37), and skin (38), which express 
little or no B7-2, and from human blood (39), functional 
maturation develops in vitro in response to appropriate cy-
tokines. This is correlated with marked upregulation of B7 
molecules (40), in particular B7-2 (2). Although DC express 
several adhesion and costimulatory molecules (CDlla, 
CD44, CD54, CD48/5B, CD80 and CD86), B7-2 appears to be 
the major CD2B1CTLA-4 ligand and accounts for the costimu-
lation provided by this pathway during in vitro immune 
responses. Indeed, in a recent study, anti-CDBO (B7-1) mAbs 
failed to inhibit human dendritic Langerhans cell-induced 
alloactivation of T cells (4Jl. Early and sustained expression 
of B7-2 mRNA (within 8 hr) (before maximal B7-1 expres-
sion) in activated murine B cells (42), suggests that it may 
provide a critical signal (within the first 24 hr) involved in 
the decision between activation or inactivation of T cells 
within 24 hr of stimulation (43, 44). Moreover, APCs from 
mice in which the B7-1 gene has been "knocked out" express 
B7-2 and are competent APCs (42). 
T cell costimulation mediated by CD28 is important in the 
mediation oftransplant rejection and the development of new 
therapeutic immunosuppressive strategies. Thus combina-
tion of anti-B7 mAb with cyclosporine A induces alloantigen-
specific anergy in vitro (45). CTLA4-Ig, a fusion protein that 
blocks the CD28-mediated costimulatory signal inhibits T 
cell proliferation in allogeneic MLR (20, 40), and induces 
hyporesponsiveness to alloantigen in vitro (20). Moreover, it 
prolongs MHC-mismatched cardiac allograft survival in rats 
(21,46) and induces donor-specific transplantation tolerance 
to skin grafts in cardiac-allografted mice (47). Propagation of 
B7-2 - cells with characteristics of DC progenitors and the 
capacity to induce alloantigen-specific hyporesponsiveness 
has significant in vivo implications. We have shown that DC 
progenitors can be propagated from the liver in response to 
GM-CSF. Conceivably, the reduced immunogenicity of liver 
allografts may be linked, at least in part. to the release of 
potentially T cell anergizing APC from the liver. a pseudohe-
mopoietic organ (48). This is likely to occur under the influ-
ence of locally-produced GM-CSF (49) and possibly other 
growth promoting cytokines. Failure of the B7-2 - cells to 
induce complete unresponSiveness (anergy) in vitro, how-
ever. suggests that considerations of the cellular therapy of 
allogratt rejection using donor-derived DC progenitors 
2° MLR:No. BI0 stimulatorsa (XI03 ) 
25 50 100 
18.54:t0.44 23.81:!:0.46 25.78:!:0.59 
247.47:!:41.l2 240.00:!:11.74 231.81:!: 1 1.06 
9.89:!:0.51 1l.34:!:0.38 13.86:!:0.78 
338.01:!: 10.50 341.24:!:46.10 291.32:!:44.05 
should include the use of adjunctive immunosuppression, 
implementing drugs or molecular approaches geared to in-
hibit costimulatory molecule expression on APC. 
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